Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AFM Grants CHF1m To Santhera
The French patient advocacy organisation, Association Française contre les Myopathies (AFM) has awarded a grant of CHF1m for the development of Santhera Pharmaceuticals’ (Santhera) SNT-317 (INN: omigapil) in
The French patient advocacy organisation, Association Française contre les Myopathies (AFM) has awarded a grant of CHF1m for the development of Santhera Pharmaceuticals’ (Santhera) SNT-317 (INN: omigapil) in
Abbott has announced that Xience Prime everolimus eluting coronary stent system and the Xience V everolimus eluting coronary stent system have received additional new CE Markings covering the
Calmune has established an exclusive research collaboration with Crucell, which focuses on research development, production and marketing of vaccines, proteins and antibodies that prevent and/or treat infectious diseases.
GATC Biotech is set to open a sequencing laboratory in London to provide scientists in UK and Ireland with single sample sequencing services. It will be situated in
Cevec Pharmaceuticals (Cevec) has reported the closing of a E4m financing round that is aimed to finance the growth of human CAP technology. Creathor Venture Fonds and NRW.BANK
Mayo Clinic Proceedings has published data from a pivotal phase III trial, which demonstrated that Nuvigil (armodafinil) Tablets [C-IV] significantly improved wakefulness throughout the shift in patients with
Idera Pharmaceuticals (Idera) has provided preclinical data on the mechanism by which IMO-2125 was shown to induce immune activation through Toll-like Receptor 9 (TLR9). IMO-2125 is a novel
Idenix Pharmaceuticals (Idenix) has initiated a phase II randomised, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and antiviral activity of IDX184 in combination with
Johnson & Johnson (J&J) has announced global restructuring initiatives designed to strengthen its position in the world’s health care industry. The company is taking steps to prioritize its
Trevena has been awarded a $7.65m Grand Opportunity (GO) Grant by the office of the director of the National Institutes of Health (NIH). The grant will further fund